PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9596759-4	1998	Reduction of the anti-paramyosin IgG4 titer following combined chemotherapy with diethylcarbamazine and ivermectin was significantly correlated with a reduction in the adult worm burden.	Ivermectin	104-114	Paramyosin, putative;Uncharacterized protein	Brugia malayi	22-32
27504249-8	2016	Ivermectin 1 % cream QD led to a significantly greater likelihood of success compared with azelaic acid 15 % gel twice-daily (BID) [relative risk (95 % credible interval): 1.25 (1.14-1.37)], and metronidazole 0.75 % cream BID [1.17 (1.08-1.29)] at 12 weeks.	Ivermectin	0-10	BH3 interacting domain death agonist	Homo sapiens	222-225
11939306-12	2002	Pharmacologic treatment with ivermectin, loperamide, vincristine, and other drugs that are substrates of P-glycoprotein, the MDR1 gene product, may result in neurologic toxicosis in a high percentage of Collies.	Ivermectin	29-39	ATP binding cassette subfamily B member 1	Canis lupus familiaris	125-129
10784170-7	2000	We suggest that enhanced prepubertal IGF-I levels in conjunction with increased prepubertal LH levels and pubertal LH pulse amplitude might be involved in the accelerated somatic maturation and in puberty advancement observed in ivermectin-treated heifers.	Ivermectin	229-239	insulin like growth factor 1	Homo sapiens	37-42
27102368-6	2016	To establish the functional relevance of this system, we used two-electrode voltage-clamp electrophysiology in Xenopus oocytes to characterize activation of crystallographic and native-like GluCl constructs by L-glutamate and ivermectin.	Ivermectin	226-236	Ig-like domain-containing protein	Caenorhabditis elegans	190-195
27231793-14	2016	For a cohort of 1,000 patients, ivermectin 1% cream QD provided an additional 72,922 disease-free days (200 years) over a 3-year period compared with metronidazole 0.75% cream BID, leading to a lower cost per disease-free day for ivermectin 1% cream QD ($4.54) compared with metronidazole 0.75% cream BID ($4.85).	Ivermectin	32-42	BH3 interacting domain death agonist	Homo sapiens	301-304
27231793-16	2016	After 3 years, ivermectin 1% cream QD was associated with the lowest health care costs ($62,767 compared with $73,284 for metronidazole 0.75% cream BID and $77,208 for azelaic acid 15% gel BID), reflecting a 15% reduction in physician visit costs, when compared with metronidazole 0.75% cream BID, and almost a 20% reduction, when compared with azelaic acid 15% gel BID.	Ivermectin	15-25	BH3 interacting domain death agonist	Homo sapiens	189-192
27231793-16	2016	After 3 years, ivermectin 1% cream QD was associated with the lowest health care costs ($62,767 compared with $73,284 for metronidazole 0.75% cream BID and $77,208 for azelaic acid 15% gel BID), reflecting a 15% reduction in physician visit costs, when compared with metronidazole 0.75% cream BID, and almost a 20% reduction, when compared with azelaic acid 15% gel BID.	Ivermectin	15-25	BH3 interacting domain death agonist	Homo sapiens	189-192
27231793-16	2016	After 3 years, ivermectin 1% cream QD was associated with the lowest health care costs ($62,767 compared with $73,284 for metronidazole 0.75% cream BID and $77,208 for azelaic acid 15% gel BID), reflecting a 15% reduction in physician visit costs, when compared with metronidazole 0.75% cream BID, and almost a 20% reduction, when compared with azelaic acid 15% gel BID.	Ivermectin	15-25	BH3 interacting domain death agonist	Homo sapiens	189-192
25865432-5	2015	Avermectins inhibited MDR1/Mdr1a-mediated H33342 dye efflux, with apparent Ki values of 0.24+-0.08 and 0.18+-0.02muM (ivermectin); 0.60+-0.07 and 0.56+-0.02muM (emamectin) and 0.95+-0.08 and 0.77+-0.25muM (abamectin) in SH-SY5Y and N2a cells, respectively.	Ivermectin	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
25865432-5	2015	Avermectins inhibited MDR1/Mdr1a-mediated H33342 dye efflux, with apparent Ki values of 0.24+-0.08 and 0.18+-0.02muM (ivermectin); 0.60+-0.07 and 0.56+-0.02muM (emamectin) and 0.95+-0.08 and 0.77+-0.25muM (abamectin) in SH-SY5Y and N2a cells, respectively.	Ivermectin	118-128	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	27-32
25801227-5	2015	After the treatment with doxycycline and ivermectine a decrease in CRP and Hp levels was experienced, which could reflect a reduction of the vascular inflammation caused by the elimination of Wolbachia and reduction of microfilariae.	Ivermectin	41-52	C-reactive protein	Canis lupus familiaris	67-70
24582422-3	2014	In this model, ivermectin, cyclosporin, verapamil, loperamide and ketoconazole inhibited P-gp function with IC50 values ranging from 0.1 to 3.7 mumol/L.	Ivermectin	15-25	PGP	Canis lupus familiaris	89-93
23086000-7	2013	In agreement with this hypothesis, the co-expression of wild-type dynamin, wild-type Rab5 or active Rab5 (Q79L) could increase the potentiation of the ATP-induced P2X4 response by ivermectin.	Ivermectin	180-190	RAB5A, member RAS oncogene family	Homo sapiens	85-89
23086000-7	2013	In agreement with this hypothesis, the co-expression of wild-type dynamin, wild-type Rab5 or active Rab5 (Q79L) could increase the potentiation of the ATP-induced P2X4 response by ivermectin.	Ivermectin	180-190	RAB5A, member RAS oncogene family	Homo sapiens	100-104
23086000-7	2013	In agreement with this hypothesis, the co-expression of wild-type dynamin, wild-type Rab5 or active Rab5 (Q79L) could increase the potentiation of the ATP-induced P2X4 response by ivermectin.	Ivermectin	180-190	purinergic receptor P2X 4	Homo sapiens	163-167
20579678-2	2011	In this study we aimed to demonstrate the effects of administration of ivermectin (anthelmentic drug, Pgp substrates), either alone or simultaneously with verapamil (Pgp inhibitor) in Wister rats on fetal development, maternal bone marrow for detection of micronuclei (MN), chromosomal aberrations and mitotic index (MI) and embryonic liver cells for cellular proliferation indicated by MI, and bleeding from umbilical vessels for detection of embryonic micronuclei (MN).	Ivermectin	71-81	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	102-105
20113248-5	2010	RESULTS: Horses with PPID had higher fecal egg counts before and 8, 10, and 12 weeks after ivermectin treatment, compared with counts for site-matched healthy horses.	Ivermectin	91-101	peptidylprolyl isomerase D	Equus caballus	21-25
7560060-1	1995	We have previously shown that absence of the mouse mdr1a (also called mdr3) P-glycoprotein in mdr1a (-/-) "knockout" mice has a profound effect on the tissue distribution and elimination of vinblastine and ivermectin, and hence on the toxicity of these compounds.	Ivermectin	206-216	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	51-56
8647944-1	1996	The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain.	Ivermectin	162-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	10-15
8647944-1	1996	The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain.	Ivermectin	162-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	29-33
8647944-1	1996	The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain.	Ivermectin	162-172	phosphoglycolate phosphatase	Mus musculus	35-39
8647944-1	1996	The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain.	Ivermectin	162-172	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	99-104
7560060-1	1995	We have previously shown that absence of the mouse mdr1a (also called mdr3) P-glycoprotein in mdr1a (-/-) "knockout" mice has a profound effect on the tissue distribution and elimination of vinblastine and ivermectin, and hence on the toxicity of these compounds.	Ivermectin	206-216	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	70-74
7560060-1	1995	We have previously shown that absence of the mouse mdr1a (also called mdr3) P-glycoprotein in mdr1a (-/-) "knockout" mice has a profound effect on the tissue distribution and elimination of vinblastine and ivermectin, and hence on the toxicity of these compounds.	Ivermectin	206-216	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	94-99
7747411-10	1995	There were no differences in serum complement or serum nitric oxide levels between the two groups at any stage, but insulin-like growth factor-1 levels were significantly reduced in serum of the ivermectin-treated group, 4 days after each drench.	Ivermectin	195-205	insulin-like growth factor I	Ovis aries	116-144
33810134-3	2021	Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux.	Ivermectin	54-64	phosphoglycolate phosphatase	Mus musculus	187-190
33810134-3	2021	Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux.	Ivermectin	54-64	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	191-196
33810134-3	2021	Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux.	Ivermectin	66-69	phosphoglycolate phosphatase	Mus musculus	187-190
33810134-3	2021	Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux.	Ivermectin	66-69	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	191-196
32797786-0	2020	Tramadol Effects on Lameness Score After Inhibition of P-GP by Ivermectin Administration in Horses: Preliminary Results.	Ivermectin	63-73	ATP binding cassette subfamily B member 1	Equus caballus	55-59
34268580-8	2021	BBB Pgp activity in the model was optimized using measured CSF data for the Pgp substrates ivermectin, indinavir, vincristine, docetaxel, paclitaxel, olanzapine and citalopram, as no useful in vitro data were available.	Ivermectin	91-101	ATP binding cassette subfamily B member 1	Homo sapiens	76-79
34917923-5	2022	Moreover, although chloroquine and ivermectin effectively inhibited the expression of LC3B in the nucleus, chloroquine specifically maintained the performance of LC3B in cytoplasm, thereby contributing to the differentiation of ciliated cells and subsequent improvement in the beating functions of the cilia, whereas ivermectin only facilitated differentiation of goblet cells.	Ivermectin	35-45	microtubule associated protein 1 light chain 3 beta	Homo sapiens	86-90
34623639-9	2022	In addition, we describe a novel GluCl subtype, made of the GLC-2/GLC-3 subunit combination, for which a high concentration of the anthelmintics ivermectin and moxidectin reversibly potentiate glutamate-induced response.	Ivermectin	145-155	Glutamate-gated chloride channel subunit beta	Caenorhabditis elegans	60-65
34623639-9	2022	In addition, we describe a novel GluCl subtype, made of the GLC-2/GLC-3 subunit combination, for which a high concentration of the anthelmintics ivermectin and moxidectin reversibly potentiate glutamate-induced response.	Ivermectin	145-155	Ig-like domain-containing protein	Caenorhabditis elegans	66-71
34843829-0	2022	Immunotoxicity induced by Ivermectin is associated with NF-kappaB signaling pathway on macrophages.	Ivermectin	26-36	nuclear factor kappa B subunit 1	Homo sapiens	56-65
34638339-5	2021	Furthermore, genetic knockdown and pharmacological inhibition of HSP27, via ivermectin treatment, significantly sensitizes ovarian cancer cells cultured on COL11A1 to cisplatin treatment.	Ivermectin	76-86	heat shock protein family B (small) member 2	Homo sapiens	65-70
34638339-5	2021	Furthermore, genetic knockdown and pharmacological inhibition of HSP27, via ivermectin treatment, significantly sensitizes ovarian cancer cells cultured on COL11A1 to cisplatin treatment.	Ivermectin	76-86	collagen type XI alpha 1 chain	Homo sapiens	156-163
34483925-6	2021	The results demonstrated that ivermectin dose-dependently inhibited colorectal cancer SW480 and SW1116 cell growth, followed by promoting cell apoptosis and increasing Caspase-3/7 activity.	Ivermectin	30-40	caspase 3	Homo sapiens	168-179
33390681-1	2021	In this study, we examined five previously synthesized compounds and checked their binding affinity towards the SARS-CoV-2 main protease (Mpro) by molecular docking study, and compared the data with three FDA approved drugs, i.e., Remdesivir, Ivermectine and Hydroxychlorochine.	Ivermectin	243-254	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	138-142
35624772-0	2022	Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy.	Ivermectin	0-10	AKT serine/threonine kinase 1	Homo sapiens	137-140
35624772-0	2022	Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy.	Ivermectin	0-10	mechanistic target of rapamycin kinase	Homo sapiens	141-145
35180394-8	2022	Finally, drugs approved by the U.S. Food and Drug Administration, namely, ivermectin and meclizine, restored ATP levels and ameliorated CM death and functional abnormalities of Orf9cOE hPSC-CMs.	Ivermectin	74-84	FAM3 metabolism regulating signaling molecule B	Homo sapiens	177-181
33462580-11	2021	CONCLUSIONS: A 3-day 1 daily dose of 400 microg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients.	Ivermectin	56-66	influenza virus NS1A binding protein	Homo sapiens	92-95
34130375-3	2021	Thus, in this current computational study we carried out molecular docking experiments to assess the bridging potentials of some commercial drugs such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, camostat, famotidine, umifenovir, nitazoxanide, ivermectin, and fluvoxamine at the interface between human ACE2 and the coronavirus spike glycoprotein complex.	Ivermectin	269-279	angiotensin converting enzyme 2	Homo sapiens	328-332
35225114-5	2022	Genetic polymorphisms in P-glycoprotein or coadministration of P-glycoprotein inhibitors may increase the neurotoxicity of ivermectin.	Ivermectin	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	25-39
35225114-5	2022	Genetic polymorphisms in P-glycoprotein or coadministration of P-glycoprotein inhibitors may increase the neurotoxicity of ivermectin.	Ivermectin	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	63-77
33867777-0	2021	The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.	Ivermectin	25-35	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	60-65
33867777-1	2021	In this study, we have investigated the binding mechanism of two FDA-approved drugs (ivermectin and levosalbutamol) with the spike protein of SARs-CoV-2 using three different computational modeling techniques.	Ivermectin	85-95	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	125-130
33867777-4	2021	Using density functional theory (DFT) studies, we have calculated the binding energies between ivermectin and levosalbutamol with residues in spike protein which favor their binding are - 22.4 kcal/mol and - 21.08 kcal/mol, respectively.	Ivermectin	95-105	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	142-147
32959166-13	2021	In vivo, the IPOalpha/beta1 inhibitor ivermectin decreased ATLL tumor burden without side effects.	Ivermectin	38-48	superoxide dismutase 1	Homo sapiens	13-27
33531790-12	2021	This finding was of particular importance that other compounds including hydroxychloroquine sulphate, lopinavir and ivermectin could bind with the spike protein only by weak Vander wall bonds and no hydrogen bond formation was noticed.	Ivermectin	116-126	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	147-152
33070345-1	2021	This study was aimed to investigate the influence of verapamil-mediated inhibition of P-glycoprotein (P-gp) on the pharmacokinetics of ivermectin (IVM) given orally and subcutaneously (SC) to rabbits.	Ivermectin	135-145	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	86-100
32950529-5	2020	This study revealed that Rifabutin, Rifapentine, Fidaxomicin, 7-methyl-guanosine-5"-triphosphate-5"-guanosine and Ivermectin have a potential inhibitory interaction with RdRp of SARS-CoV-2, and could be effective drugs for COVID-19.	Ivermectin	114-124	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	170-174
33070345-1	2021	This study was aimed to investigate the influence of verapamil-mediated inhibition of P-glycoprotein (P-gp) on the pharmacokinetics of ivermectin (IVM) given orally and subcutaneously (SC) to rabbits.	Ivermectin	135-145	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	102-106
33070345-1	2021	This study was aimed to investigate the influence of verapamil-mediated inhibition of P-glycoprotein (P-gp) on the pharmacokinetics of ivermectin (IVM) given orally and subcutaneously (SC) to rabbits.	Ivermectin	147-150	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	86-100
33070345-1	2021	This study was aimed to investigate the influence of verapamil-mediated inhibition of P-glycoprotein (P-gp) on the pharmacokinetics of ivermectin (IVM) given orally and subcutaneously (SC) to rabbits.	Ivermectin	147-150	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	102-106
32461053-0	2021	Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.	Ivermectin	8-18	histocompatibility minor 13	Homo sapiens	95-98
32752944-5	2021	Hydroxychloroquine and ivermectin have been identified to act by creating the acidic condition in cells and inhibiting the importin (IMPalpha/beta1) mediated viral import.	Ivermectin	23-33	inositol monophosphatase 1	Homo sapiens	133-147
33014317-5	2020	Methods: Using some docking methods, RdRP was targeted by Milbemycins (MMs), Ivermectin (IMT), Baloxavir Marboxil (BM), and Tadalafil (TF), a phosphodiesterase type 5 inhibitor.	Ivermectin	77-87	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	37-41
33014317-7	2020	Conclusion: The drugs used in the present computational investigation are effective against the SARS-CoV-2 RdRP with high affinity values especially, milbemycins, ivermectin, and Baloxavir marboxil, which could further be studied in laboratory and clinical trials for saving millions of lives around the world.	Ivermectin	163-173	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	107-111
32322397-5	2020	Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPalpha/beta1) mediated viral import.	Ivermectin	23-33	importin	None	106-114
32322397-5	2020	Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPalpha/beta1) mediated viral import.	Ivermectin	23-33	inositol monophosphatase 1	Homo sapiens	116-130
32039764-4	2020	The molecular mechanism of action of ivermectin, focusing on Akt/mTOR signaling, was elucidated.	Ivermectin	37-47	thymoma viral proto-oncogene 1	Mus musculus	61-64
31845908-0	2020	Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models.	Ivermectin	0-10	heat shock protein family B (small) member 1	Homo sapiens	20-25
31845908-4	2020	Ivermectin directly binds this pocket to inhibit MAPKAP2-mediated HSP27 phosphorylation and depolymerization, thereby blocking HSP27-regulated survival signaling and client-oncoprotein interactions.	Ivermectin	0-10	heat shock protein family B (small) member 1	Homo sapiens	66-71
31845908-4	2020	Ivermectin directly binds this pocket to inhibit MAPKAP2-mediated HSP27 phosphorylation and depolymerization, thereby blocking HSP27-regulated survival signaling and client-oncoprotein interactions.	Ivermectin	0-10	heat shock protein family B (small) member 1	Homo sapiens	127-132
31845908-5	2020	Ivermectin potentiated activity of anti-androgen receptor and anti-EGFR drugs in prostate and EGFR/HER2-driven tumor models, respectively, identifying a repurposing approach for cotargeting stress-adaptive responses to overcome resistance to inhibitors of oncogenic pathway signaling.	Ivermectin	0-10	epidermal growth factor receptor	Homo sapiens	67-71
31845908-5	2020	Ivermectin potentiated activity of anti-androgen receptor and anti-EGFR drugs in prostate and EGFR/HER2-driven tumor models, respectively, identifying a repurposing approach for cotargeting stress-adaptive responses to overcome resistance to inhibitors of oncogenic pathway signaling.	Ivermectin	0-10	epidermal growth factor receptor	Homo sapiens	94-98
31845908-5	2020	Ivermectin potentiated activity of anti-androgen receptor and anti-EGFR drugs in prostate and EGFR/HER2-driven tumor models, respectively, identifying a repurposing approach for cotargeting stress-adaptive responses to overcome resistance to inhibitors of oncogenic pathway signaling.	Ivermectin	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
32039764-0	2020	Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.	Ivermectin	0-10	thymoma viral proto-oncogene 1	Mus musculus	111-114
32039764-4	2020	The molecular mechanism of action of ivermectin, focusing on Akt/mTOR signaling, was elucidated.	Ivermectin	37-47	mechanistic target of rapamycin kinase	Mus musculus	65-69
32039764-0	2020	Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.	Ivermectin	0-10	mechanistic target of rapamycin kinase	Mus musculus	115-119
32039764-7	2020	Mechanistically, ivermectin suppressed the phosphorylation of key molecules in the Akt/mTOR signaling pathway in ovarian cancer cells.	Ivermectin	17-27	thymoma viral proto-oncogene 1	Mus musculus	83-86
32039764-7	2020	Mechanistically, ivermectin suppressed the phosphorylation of key molecules in the Akt/mTOR signaling pathway in ovarian cancer cells.	Ivermectin	17-27	mechanistic target of rapamycin kinase	Mus musculus	87-91
32039764-8	2020	In addition, overexpression of constitutively active Akt restored ivermectin-induced inhibition of Akt/mTOR, growth arrest and apoptosis.	Ivermectin	66-76	thymoma viral proto-oncogene 1	Mus musculus	53-56
32039764-8	2020	In addition, overexpression of constitutively active Akt restored ivermectin-induced inhibition of Akt/mTOR, growth arrest and apoptosis.	Ivermectin	66-76	thymoma viral proto-oncogene 1	Mus musculus	99-102
32039764-8	2020	In addition, overexpression of constitutively active Akt restored ivermectin-induced inhibition of Akt/mTOR, growth arrest and apoptosis.	Ivermectin	66-76	mechanistic target of rapamycin kinase	Mus musculus	103-107
31658701-2	2019	In this study, we found that p21-activated kinase (PAK1) inhibitor (Group I, PAK inhibitor, IPA-3) and inactivator (ivermectin) treatments inhibit cell proliferation and that tumor growth of PAK1-knockout cells in a mouse model is significantly reduced.	Ivermectin	116-126	p21 (RAC1) activated kinase 1	Mus musculus	191-195
32056710-6	2020	Treatment of ZIKV-infected cells with importin alpha/beta-NS5 interaction inhibitors ivermectin or 4-HPR resulted in a rapid degradation of NS5 similar to the R393 A/N mutations.	Ivermectin	85-95	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	58-61
31755894-0	2019	Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells.	Ivermectin	0-10	AKT serine/threonine kinase 1	Homo sapiens	61-64
31755894-0	2019	Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells.	Ivermectin	0-10	mechanistic target of rapamycin kinase	Homo sapiens	65-69
31755894-12	2019	Mechanistically, IVM induced autophagy through AKT/mTOR signaling and induced energy impairment.	Ivermectin	17-20	AKT serine/threonine kinase 1	Homo sapiens	47-50
31755894-12	2019	Mechanistically, IVM induced autophagy through AKT/mTOR signaling and induced energy impairment.	Ivermectin	17-20	mechanistic target of rapamycin kinase	Homo sapiens	51-55
31611793-8	2019	The P2X4R positive allosteric modulator, ivermectin, increased the negative chronotropic response of ATP.	Ivermectin	41-51	purinergic receptor P2X 4	Homo sapiens	4-9
31601244-7	2019	We evaluated the in vitro cestocidal and apoptotic effects of NLCs-loaded IVM versus IVM by quantifying the expression of caspase-3 mRNA.	Ivermectin	74-77	caspase 3	Homo sapiens	122-131
31601244-10	2019	Additionally, we found that NLCs-loaded IVM induced higher mRNA caspase-3 expression suggesting a more potent apoptotic effect on the parasite.	Ivermectin	40-43	caspase 3	Homo sapiens	64-73
30454072-9	2018	Lastly, we identified that the compound ivermectin, as well as riluzole, reduced HSR activation in both C9-ALS/FTD and SOD1 zebrafish models.Thus, our C9-ALS/FTD zebrafish model is a stable transgenic model which recapitulates key features of human C9orf72-ALS/FTD, and represents a powerful drug-discovery tool.	Ivermectin	40-50	superoxide dismutase 1, soluble	Danio rerio	119-123
30454072-9	2018	Lastly, we identified that the compound ivermectin, as well as riluzole, reduced HSR activation in both C9-ALS/FTD and SOD1 zebrafish models.Thus, our C9-ALS/FTD zebrafish model is a stable transgenic model which recapitulates key features of human C9orf72-ALS/FTD, and represents a powerful drug-discovery tool.	Ivermectin	40-50	C9orf72-SMCR8 complex subunit	Homo sapiens	249-256
28093773-4	2017	Many drugs commonly used in veterinary medicine are known substrates for canine P-gp (vincristine, loperamide, ivermectin, others).	Ivermectin	111-121	PGP	Canis lupus familiaris	80-84
28061549-1	2017	Dogs with a 4-bp deletion in the MDR1 (or ABCB1) gene show intolerance to certain drugs routinely used in veterinary medicine, such as ivermectin, vincristine, and doxorubicin.	Ivermectin	135-145	ATP binding cassette subfamily B member 1	Canis lupus familiaris	33-37
28061549-1	2017	Dogs with a 4-bp deletion in the MDR1 (or ABCB1) gene show intolerance to certain drugs routinely used in veterinary medicine, such as ivermectin, vincristine, and doxorubicin.	Ivermectin	135-145	ATP binding cassette subfamily B member 1	Canis lupus familiaris	42-47
30323047-8	2019	No evident effect was observed for tribendimidine-oxantel pamoate at the CYP450 metabolism level, whereas a combination of tribendimidine and ivermectin led to moderately increased CYP2D6 inhibition compared to ivermectin or tribendimidine alone.	Ivermectin	142-152	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	181-187